Compare PXS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PXS | RFL |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.8M | 61.1M |
| IPO Year | N/A | 2017 |
| Metric | PXS | RFL |
|---|---|---|
| Price | $3.98 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 80.3K | ★ 103.5K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | $28.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $2.47 | $1.12 |
| 52 Week High | $4.74 | $3.19 |
| Indicator | PXS | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 54.24 | 52.39 |
| Support Level | $2.69 | $1.35 |
| Resistance Level | $4.74 | $1.38 |
| Average True Range (ATR) | 0.29 | 0.12 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 24.57 | 32.73 |
Pyxis Tankers Inc is an international maritime transportation company focused on mid-sized eco-vessels for the product tanker and dry-bulk sectors. It owns a fleet that comprises double-hull product tankers employed under a mix of short- and medium-term time charters and spot charters. The fleet owned by the company includes Konkar Ormi, Pyxis Lamda, Konkar Venture, Pyxis Karteria, and others. Each of the vessels in the fleet is capable of transporting refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, fuel oil, and other liquid bulk items, such as vegetable oils and organic chemicals. The company operates under two reportable segments, Tanker Vessels, which derive maximum revenue, and Dry-bulk Vessels.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.